This is a comprehensive review paper that looks back at all the major treatment advances in breast cancer over the past decade (2015 to 2025). Rather than reporting new experimental results, it synthesizes and explains the most important clinical trials, drug approvals, and scientific discoveries that have changed how breast cancer is treated.
Breast cancer is the most commonly diagnosed cancer worldwide. But treatment has advanced more rapidly in this decade than ever before, thanks to new targeted medicines, improved immune-based therapies, modern drug-delivery technologies, and highly precise molecular diagnostic tools that make it possible to tailor treatment to the unique biology of each tumor.
The review covers all main breast cancer subtypes, including hormone receptor-positive (HR+), HER2-positive, and triple-negative breast cancer (TNBC), which is historically the hardest to treat.
TL;DR: A comprehensive look back at 10 years of breast cancer treatment breakthroughs, covering all major subtypes and therapy types.
HR+ Cancer
Hormone Receptor-Positive Breast Cancer: CDK4/6 Inhibitors Changed Everything
About 70% of all breast cancers are hormone receptor-positive (HR+), meaning they grow in response to hormones like estrogen. The biggest game-changer for these patients has been a class of drugs called CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib).
These drugs work by blocking proteins called CDK4 and CDK6, which cancer cells need in order to divide and multiply. By shutting down this cell division machinery, the drugs essentially put the brakes on tumor growth. When combined with standard hormone therapy, CDK4/6 inhibitors have dramatically extended the time patients live without their cancer progressing.
Clinical trials like PALOMA, MONARCH, and MONALEESA showed that adding these drugs to hormone therapy nearly doubled progression-free survival in many patients. They have become the standard of care for advanced HR+ breast cancer.
TL;DR: CDK4/6 inhibitors, combined with hormone therapy, nearly doubled progression-free survival for the 70% of breast cancer patients with hormone-driven tumors.
HER2+
HER2-Targeted Therapy: From Herceptin to Antibody-Drug Conjugates
About 15-20% of breast cancers overexpress a protein called HER2 (Human Epidermal Growth Factor Receptor 2), which drives aggressive tumor growth. The drug trastuzumab (Herceptin), approved back in 1998, was the original breakthrough for these patients.
But the past decade saw a new generation of treatments. Antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-DXd, brand name Enhertu) combine a HER2-targeting antibody with a potent chemotherapy payload. The antibody acts like a homing missile that finds HER2-positive cancer cells, then releases the chemo drug directly inside them. This means the chemotherapy is delivered right where it is needed, with far less damage to healthy tissue.
The DESTINY-Breast trials showed remarkable responses with T-DXd, even in patients whose cancers had very low levels of HER2. This expanded the pool of patients who could benefit from HER2-targeted treatment and redefined what 'HER2-positive' means.
TL;DR: Antibody-drug conjugates like Enhertu act as 'homing missiles' that deliver chemo directly into cancer cells, working even in tumors with low HER2 levels.
TNBC
Triple-Negative Breast Cancer: Finally Getting Targeted Options
Triple-negative breast cancer (TNBC) lacks the three receptors (estrogen, progesterone, and HER2) that most breast cancer drugs target. For decades, chemotherapy was essentially the only option, and outcomes were poor.
The past decade brought the first real targeted treatments for TNBC. Immunotherapy with checkpoint inhibitors (like pembrolizumab/Keytruda) was approved for certain TNBC patients after the KEYNOTE-522 trial showed it improved outcomes when combined with chemotherapy, particularly for patients whose tumors express a protein called PD-L1.
Additionally, sacituzumab govitecan (Trodelvy), another antibody-drug conjugate, showed significant benefit in previously treated TNBC patients. PARP inhibitors like olaparib have also become an option for TNBC patients with inherited BRCA gene mutations. These advances mean TNBC patients finally have treatment options beyond just chemotherapy.
TL;DR: TNBC, once treatable only with chemo, now has immunotherapy (Keytruda), antibody-drug conjugates (Trodelvy), and PARP inhibitors for BRCA-mutated patients.
Immunotherapy
Immunotherapy: Teaching the Immune System to Fight Cancer
Immunotherapy works by helping the patient's own immune system recognize and attack cancer cells. Cancer cells often hide from the immune system by expressing 'don't eat me' signals on their surface. Checkpoint inhibitors block these signals, essentially removing the cancer's disguise so immune cells can find and destroy it.
In breast cancer, the most important immunotherapy advance has been pembrolizumab (Keytruda) combined with chemotherapy for early and advanced TNBC. The KEYNOTE-522 trial showed that adding pembrolizumab to neoadjuvant chemotherapy (given before surgery) significantly increased the rate of pathological complete response, meaning no cancer could be found when the tumor was removed.
Research is ongoing into combining immunotherapy with other treatments, using cancer vaccines to prime the immune system, and identifying biomarkers that predict which patients will respond best to immune-based treatments.
TL;DR: Checkpoint inhibitors 'unmask' cancer cells so the immune system can attack them. Keytruda combined with chemo is now standard for certain TNBC patients.
Future
What Comes Next: Precision Medicine and Beyond
The overarching trend of the past decade is a move toward precision medicine, where treatment decisions are based on the specific molecular characteristics of each patient's tumor rather than a one-size-fits-all approach.
Advances in genomic profiling (like Oncotype DX and MammaPrint tests) now help doctors determine which patients need chemotherapy and which can safely skip it. Liquid biopsies, which detect tumor DNA circulating in the blood, are being developed as tools for early detection, monitoring treatment response, and catching cancer recurrence earlier.
The review concludes that while significant progress has been made, challenges remain. Drug resistance continues to be a problem, and access to these newer, more expensive treatments is uneven globally. The next frontier involves combining multiple targeted approaches, developing even more precise biomarkers, and ensuring these advances reach all patients who need them.
TL;DR: Treatment is becoming increasingly personalized based on tumor genetics. Liquid biopsies and genomic profiling are helping doctors make smarter treatment decisions.